A Case Report of Promising Response to Combination Therapy With an Immune Checkpoint Inhibitor (Pembrolizumab) and Multi‐Targeted Tyrosine Kinase Inhibitor (Pazopanib) in Metastatic De‐Differentiated Chondrosarcoma

Key findings from this study

• The study found that pembrolizumab and pazopanib combination therapy produced clinical response in metastatic DDCS.
• The authors report that current standard-of-care approaches provide limited systemic treatment options for advanced DDCS.
• The case demonstrates potential value of combining immune checkpoint inhibition with multi-targeted tyrosine kinase inhibition in this sarcoma subtype.

Overview

A case report documents clinical response to combination pembrolizumab and pazopanib in a patient with metastatic dedifferentiated chondrosarcoma (DDCS). Standard-of-care systemic therapies for advanced DDCS remain limited, making emerging treatment approaches clinically significant.

Methods and approach

The clinical case presents a single patient with metastatic DDCS treated with concurrent immune checkpoint inhibition and multi-targeted tyrosine kinase inhibition. The case illustrates emerging dual-mechanism systemic therapy application in an advanced malignancy with restricted therapeutic options.

Results

The combination of pembrolizumab and pazopanib demonstrated promising clinical response in this DDCS patient. The case exemplifies potential synergistic benefit from pairing immunotherapy with targeted kinase inhibition in a disease context where effective systemic treatment modalities remain scarce. Treatment tolerability and specific response parameters are documented within the case narrative.

Implications

This case contributes evidence supporting exploration of multi-mechanism systemic approaches for metastatic DDCS beyond conventional surgical and chemotherapeutic strategies. The findings suggest immunotherapy combined with tyrosine kinase inhibition warrants further investigation in larger patient cohorts with DDCS. Such dual-targeted strategies may expand therapeutic options in sarcomas historically resistant to systemic intervention.

Scope and limitations

This summary is based on the study abstract and available metadata. It does not include a full analysis of the complete paper, supplementary materials, or underlying datasets unless explicitly stated. Findings should be interpreted in the context of the original publication.